Vor Biopharma (VOR) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.90
- Estimate
- -$0.72
- Surprise
- -25.3%
- Score today
- 5.8/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Vor Biopharma (VOR) reported a wider loss than forecast — adjusted EPS of -$0.90 against the -$0.72 estimate (a 25.3% shortfall).
Coverage in the report window
- Vor Biopharma Reports Third Quarter 2026 Financial Results and Corporate Update — fiscal.ai, 2026-10-30
- Vor Biopharma Files Prospectus For Offering $150M Common Shares — benzinga, 2026-10-30
Where TrendMatrix's rating stands now
TrendMatrix currently rates VOR Sell at 5.8/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -25.3% surprise compares with a +8634.1% four-quarter average. Next scheduled report: 2027-03-16.
What argues against it
- Concentration risk — Pipeline: telitacicept
- Concentration risk — Counterparty: RemeGen
- Quality below floor (1.5 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $19.19
- Price target
- $33.93
- Stop
- $17.85
- Upside to target
- +76.8%
- Reward-to-risk
- 5.7:1
Risk check: trading volume is running 2.0× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-20 — shown for context, not personalized investment advice.
VOR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.14B
- P/E (fwd)
- -5.5
- P/E (ttm)
- 0.1
- 52-week range
- $6.50–$26.00
- Off 52-week high
- 26.2%
- RSI (14)
- 50
- Volume vs avg
- 2.03×
- Score today
- 5.8/10